Table 1.
Patient medical history and disease status prior to the initiation of therapy (N = 27)
| UPN | Age at diagnosis, y | Sex | Organ involvement at diagnosis | Initial therapy | No. of reactivations | Therapy of reactivation before inclusion | Duration from diagnosis to inclusion, mo | Disease extension at start |
|---|---|---|---|---|---|---|---|---|
| 1506648 | 1.67 | M | Bone, skin, ENT, hematologic | VBL + steroid 2 inductions, maintenance 6 mo | 2 | VBL + steroid 1 induction | 9.7 | MS RO+ lung, hematologic, liver, spleen, bone |
| 1506863 | 0.17 | M | Bone, skin, hematologic, liver, spleen, lung, gingiva | VBL + steroid 2 inductions | 1 | 8.6 | MS RO+ bone, skin, hematologic, liver, spleen, lung, gingiva | |
| 1506802 | 3.34 | F | Bone, skin, pituitary, ENT | VBL + steroid 2 inductions | 1 | 6.4 | MS RO+ bone, skin, pituitary, ENT, liver, spleen, hematologic | |
| 1506961 | 0.5 | M | Bone, skin, ENT (external auditory canal), lung, hematologic, liver, nodes, thymus, | VBL + steroid 2 inductions | 1 | 3.4 | MS RO+ bone, lung, hematologic, liver, skin, nodes, thymus, external auditory canal | |
| 1506962 | 0.42 | M | Liver, skin, hematologic, alimentary canal | VBL + steroid 1 induction | 1 | 4.1 | MS RO+ liver, skin, hematologic, gut | |
| 1507009 | 1 | M | Bone, skin, ENT, liver, hematologic, | VBL + steroid 2 inductions | 1 | 3.2 | MS RO+ liver, hematologic, skin, bone, ENT | |
| 1506970 | 0.67 | F | Bone, skin, ENT (external auditory canal) | VBL + steroid 1 induction | 3 | VBL + steroid 1 induction | 12.9 | MS RO+ hematologic, GI, ENT, genital mucosa, liver, spleen |
| 1507092 | 0.67 | M | Bone, skin, liver, spleen, lung, nodes, hematologic, GI | VBL + steroid 1 induction + | 1 | 1.2 | MS RO+ skin, liver, spleen, lung, bone, nodes, hematologic, GI | |
| 1507202 | 0.67 | M | Bone, skin, hematologic | VBL + steroid 1 induction | 1 | 2.3 | MS RO+ skin, bone, hematologic, liver, spleen | |
| 1507020 | 1.42 | M | Bone, skin, liver, hematologic, spleen | VBL + steroid 2 inductions | 2 | VBL + steroid 1 induction | 16.5 | MS RO+ liver, spleen, lung, hematologic, GI |
| 1507220 | 0.67 | M | Bone, skin | VBL + steroid 1 induction + | 2 | VBL + steroid 1 induction | 12.9 | MS RO+ hematologic, bone, gingival mucosa, GI |
| 1507379 | 1.5 | M | Skin | Topical mustard | 2 | VBL + steroid 1 induction | 13.0 | MS RO+ bone, skin, ENT, liver, hematologic, GI (hypoalbuminemia), external auditory canal |
| 1507361 | 2.5 | M | Bone, hematologic, nodes, lung, fever | VBL + steroid 1 induction | 2 | VBL + steroid 1 induction | 14.5 | MS RO+ anemia, bone, hypoalbuminemia, fever, GI, lung |
| 1507236 | 0.58 | F | Skin, ENT, nodes, spleen, hematologic, liver | VBL + steroid 2 inductions | 1 | 3.9 | MS RO+ liver, hematologic, skin, spleen, gut | |
| 1507241 | 1.67 | M | Bone, skin, hematologic, liver, spleen, thyroid, lung, GI | VBL + steroid 1 induction | 1 | 1.0 | MS RO+ bone, skin, hematologic, liver, spleen, thyroid, lung, gut | |
| 1507473 | 2.0 | F | Bone, skin, liver, spleen | VBL + steroid | 1 | 8.9 | MS RO+ bone, skin, spleen gut, lung | |
| 1507255 | 0.58 | M | Bone, skin, spleen, hematologic, liver | VBL + steroid | 1 | 1.9 | MS RO+ spleen, hematologic, liver, skin, bone | |
| 3000050 | 0.08 | F | Hematologic, skin, gut, liver, spleen | VBL + steroid | 1 | 2.4 | MS RO+ hematologic, skin, gut, liver, spleen | |
| 3000051 | 1.16 | M | Bone, skin, hematologic, liver, lung, GI, nodes | VBL + steroid then VP16 steroid CSA | 1 | 3.7 | MS RO+ skin, hematologic, liver, lung, gut | |
| 3000052 | 0.6 | M | Skin, node | No therapy | 3 | VBL + steroid 2 inductions | 26.0 | MS RO+ liver, spleen, hematologic, lung, fever |
| 3000053 | 1.5 | F | Bone, skin, ENT (inner ear), nodes | VBL + steroid 1 induction then maintenance | 2 | Cladribine 5 courses, CD 75 mg/m2 | 12.0 | MS RO+ bone, CNS, ENT, nodes, hematologic |
| 3000054 | 0.7 | M | Skin | No therapy | 2 | VBL + steroid 1 induction | 4.1 | MS RO+ skin, fever, liver, spleen, hematologic, bone |
| 3000055 | 1.66 | F | Bone, CNS tumor, ENT, nodes, hematologic, liver, spleen | VBL + steroid 2 courses | 1 | 4.7 | MS RO+ bone, CNS tumor, ENT, nodes, hematologic, liver, spleen | |
| 3000057 | 0.66 | M | Skin, nodes, hematologic, liver, GI | VBL + steroid 1 induction | 1 | 4.6 | MS RO+ hematologic, liver, skin, GI, spleen | |
| 3000058 | 1.25 | F | Skin, liver, hematologic, nodes, spleen | VBL + steroid 1 induction | 1 | 2.7 | MS RO+ skin, liver, hematologic, nodes, spleen, lung | |
| 3000059 | 0.003 | M | Skin | Surgery | 2 | VBL + steroid 1 induction | 3.1 | MS RO+ skin, liver, spleen, hematologic, bone, lung, nodes |
| 3000069 | 1.5 | M | Bone, soft tissue, ENT | Topical mustard | 1 | VBL + steroid 1 induction maintenance | 12.1 | MS RO+ bone, soft tissue, ENT, spleen, liver, skin, hematologic |
CD, cumulative dose; CNS, central nervous system; CSA, cyclosporine A; ENT, ear, nose, and throat; F, female; GI, gastrointestinal; M, male; MS RO+, multisystem risk-organ positive; UPN, unique patient number.